Fox Run Management L.L.C. Raises Stock Position in Kodiak Sciences Inc. $KOD

Fox Run Management L.L.C. increased its holdings in shares of Kodiak Sciences Inc. (NASDAQ:KOD) by 136.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,419 shares of the company’s stock after purchasing an additional 16,961 shares during the period. Fox Run Management L.L.C.’s holdings in Kodiak Sciences were worth $823,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in KOD. EverSource Wealth Advisors LLC lifted its holdings in shares of Kodiak Sciences by 1,221.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 991 shares of the company’s stock valued at $28,000 after buying an additional 916 shares during the period. GF Fund Management CO. LTD. acquired a new position in shares of Kodiak Sciences in the 4th quarter valued at about $29,000. Cerity Partners LLC lifted its holdings in shares of Kodiak Sciences by 7.4% in the 4th quarter. Cerity Partners LLC now owns 16,446 shares of the company’s stock valued at $460,000 after buying an additional 1,139 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Kodiak Sciences in the 4th quarter valued at about $72,000. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Kodiak Sciences by 89.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company’s stock valued at $104,000 after buying an additional 3,009 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Analysts Set New Price Targets

KOD has been the subject of several analyst reports. Wall Street Zen raised Kodiak Sciences from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. UBS Group raised their price target on shares of Kodiak Sciences from $50.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 27th. Chardan Capital upgraded shares of Kodiak Sciences from a “neutral” rating to a “buy” rating and raised their price target for the company from $14.00 to $61.00 in a research report on Monday, May 11th. Finally, HC Wainwright restated a “buy” rating and set a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a research report on Friday, March 27th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $42.14.

Kodiak Sciences Price Performance

Shares of Kodiak Sciences stock opened at $31.41 on Thursday. The stock has a market capitalization of $1.97 billion, a P/E ratio of -7.53 and a beta of 2.21. Kodiak Sciences Inc. has a 12 month low of $3.43 and a 12 month high of $47.84. The business has a 50 day simple moving average of $39.55 and a two-hundred day simple moving average of $30.47.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.01). As a group, research analysts anticipate that Kodiak Sciences Inc. will post -3.89 EPS for the current fiscal year.

About Kodiak Sciences

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.